

## **ATTORNEY DOCKET NO.: 2001605-0007**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Ensley

Examiner:

Serial No:

09/498,305

Art Unit:

Filing Date:

February 4, 2000

Title:

WOUND HEALING COMPOSITIONS AND METHODS USING

TROPOELASTIN AND LYSYL OXIDASE

Assistant Commissioner of Patents Washington, DC 20231

Sir:

#### TRANSMITTAL LETTER

Enclosed are the following documents:

- 1. Information Disclosure Statement
- 2. Statement Filed Pursuant to the Duty of Disclosure Under 37 CFR §§1.56. 1.97 and 1.98
- 3. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

Brenda Herschbach Jarrell, Ph.D.

Reg. No. 39,223

CHOATE, HALL & STEWART Exchange Place 53 State Street Boston, MA 02109 (617) 248-5000

Dated: April /6, 2000

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231

Exchange.3106024.1





Applicant:

Ensley, Burt D.

Serial No.:

09/498,305

Filing Date:

February 4, 2000

Title:

WOUND HEALING COMPOSITIONS AND METHODS

Examiner:

Art Unit:

USING TROPOELASTIN AND LYSYL OXIDASE

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, DC 20231

Sir:

# STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants respectfully request consideration of this Information Disclosure Statement.

## PART I: Compliance with 37 C.F.R. §1.97

(Select A, B or C below)

- A. [X] This Information Disclosure Statement has been filed: (check 1, 2 and/or 3 below)
  - 1. [] within three months of the filing date of the above identified U.S. Patent application;
  - 2. [] within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International application; and/or
  - 3. [X] before the mailing date of the first Office Action on the merits in the above-identified application.

No fee or certification is required.

B. [] This Information Disclosure Statement has been filed more than three								
		after the filing date of the present application and after the mailing date o						
first Office Action, but before the mailing date of either a final act								
			37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311.					
			2 below)					
	1.	[]	The fee of \$240 as set forth in 37 C.F.R. §1.17(p) is enclosed; or					
	2.	[]		plicants hereby certify, as specified in 37 C.F.R. §1.97(e), that				
				ck a or b below)				
		a.	[]	each item of information contained in this Information				
				Disclosure Statement was cited in a communication from a				
				foreign Patent Office in a counterpart for this application not				
				more than three months prior to the filing of this Statement; or				
		b.	[]	no item of information contained in this Information Disclosure				
				Statement was cited in a communication from a foreign Patent				
				Office in a counterpart for this application or, to the knowledge				
				of the undersigned after making reasonable inquiry, was known				
				to any individual designated in 37 C.F.R. §1.56(c) more than				
				three months prior to the filing of this Statement.				
		c.	[]	items indicated by an asterisk were identified in a recent review of related files.				
C.	[]	This Information Disclosure Statement has been filed after the mailing date of						
		either a Final action under 37 C.F.R. §1.113 or a Notice of Allowance under						
		37 C.F.R. §1.311 and before payment of an Issue Fee.						
		(check 1, 2, and 3 below)						
	1.	[]	The A	applicant hereby certifies, as specified in 37 C.F.R. §1.97(e),				
			that:					
			(check a or b below)					
		a.	[]	each item of information contained in this Information				
				Disclosure Statement was cited in a communication from a				

				foreign Patent Office in a counterpart for this application not				
				more than three months prior to the filing of this Statement.				
		b.	[ ]	no item of information contained in this Information Disclosure				
				Statement was cited in a communication from a foreign Patent				
				Office in a counterpart for this application or, to the knowledge				
				of the undersigned after making reasonable inquiry, was known				
				to any individual designated in 37 C.F.R. §1.56(c) more than				
				three months prior to the filing of this Statement.				
	2.	[ ]	A Petit	tion requesting consideration of the Information Disclosure				
			Stateme	ent is attached.				
	3.	[ ]	The Pe	etition Fee of \$130 as set forth in 37 C.F.R. §1.17(i)(1) is				
			enclose	ed.				
PART II - Information Cited								
A. [X] The Applicant hereby makes of record in the above-identified application				hereby makes of record in the above-identified application the				
		refere	nce(s) lis	sted on the attached form PTO-1449 (modified). The order of				
		presen	itation of	the references should not be construed as an indication of the				
		import	tance of	the references.				
B.	[]	The Applicant hereby makes the following additional information of record in						
		the above-identified application:						
PART	CIII: E	<u>xplanati</u>	on of No	on-English Language References and Remarks Concerning Other				
Inform	nation (	Cited						
A.	[ ]	The fo	llowing i	is a concise explanation of the relevance of each non-English				
		langua	ge refere	nce listed on the attached form PTO-1449 (modified):				
В.	[]	The fol	llowing a	are remarks concerning the other information cited:				

B.

### PART IV: Remarks

- A. [X] Copies of references (check 1 or 2 below)
  - 1. [X] A copy of each of the references cited on the attached form PTO-1449 (modified) is enclosed;
  - 2. [ ] Copies of certain of the references cited on the attached form PTO-1449 (modified) are not enclosed because each of these references (indicated by asterisk) was previously cited by or submitted to the Office in a prior application, which prior application is relied upon for an earlier filing date under 35 U.S.C. § 120.
- B. [X] It is respectfully requested that: (check 1, 2, and 3 below)
  - 1. [X] The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
  - 2. [X] The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application;
  - 3. [X] The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.
- C. [X] By submitting this Information Disclosure Statement, Applicants make no representation that a search has been performed, of the extent of any search performed, or that more material information may not exist.
- D. [X] By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

- E. [X] By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.
- F. [X] Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

An early and favorable action is hereby requested.

Please charge any additional fees or credit any overpayments to our Deposit Account No. 03-1721.

Respectfully submitted,

Brenda Herschbach Jarrell, Ph.D.

Registration Number 39,223

CHOATE, HALL & STEWART Exchange Place 53 State Street Boston, Massachusetts 02109 (617) 248-5000

Dated: April 18, 2000

I hereby certify that this correspondence is Beau, deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistate Commissioner For Patents, Washington, D.C. 2023

Exchange.3113007.1